MarketCap
Facebook
X
Telegram
Check-Cap Ltd. Market Cap | CHEK
As of October 26, 2026 Check-Cap Ltd. has a market cap of $ 9.42 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Check-Cap Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 4.33 M | 13.3 M | 15.6 M | 2.55 M | 2.11 M | 11.8 M | 7.79 B | 12.6 B | 33.7 M | 24.4 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.6 B | 2.11 M | 2.05 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
6.09 M | $ 1.73 | 2.98 % | $ 5.04 M | USA |
 |
Myriad Genetics
MYGN
|
409 M | $ 5.93 | 1.87 % | $ 549 M | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 2.27 | 7.58 % | $ 681 M | USA |
 |
Neuronetics
STIM
|
81.1 M | $ 2.24 | 5.92 % | $ 148 M | USA |
 |
Agilent Technologies
A
|
31.5 B | $ 175.71 | 1.56 % | $ 49.9 B | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 354.37 | 2.67 % | $ 17.6 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
554 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
9.41 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 11.95 | 1.1 % | $ 126 M |  China |
 |
Renalytix AI plc
RNLX
|
22.7 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Bioventus
BVS
|
608 M | $ 14.71 | -1.67 % | $ 980 M | USA |
 |
Psychemedics Corporation
PMD
|
16.8 M | - | -1.84 % | $ 15.3 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.3 B | $ 26.77 | -0.48 % | $ 25.4 B |  Niderland |
 |
Meridian Bioscience
VIVO
|
1.38 B | - | - | $ 1.49 B | USA |
 |
Accelerate Diagnostics
AXDX
|
4.03 M | - | -61.36 % | $ 2.46 M | USA |
 |
T2 Biosystems
TTOO
|
7.78 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Celcuity
CELC
|
5.37 B | $ 66.71 | 2.26 % | $ 3.12 B | USA |
 |
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 0.56 | 3.12 % | $ 745 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 241.85 | 0.02 % | $ 26.8 B | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 232.05 | 0.7 % | $ 165 B | USA |
 |
DexCom
DXCM
|
25.5 B | $ 77.69 | -0.33 % | $ 30.3 B | USA |
 |
Castle Biosciences
CSTL
|
472 M | $ 33.16 | 0.24 % | $ 961 M | USA |
 |
Fulgent Genetics
FLGT
|
527 M | $ 20.41 | 1.54 % | $ 628 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 174.47 | 3.19 % | $ 21.9 B | USA |
 |
Quotient Limited
QTNT
|
237 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
IDEXX Laboratories
IDXX
|
51.1 B | $ 568.76 | 1.5 % | $ 45.7 B | USA |
 |
Illumina
ILMN
|
25.3 B | $ 271.02 | 0.59 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 275.32 | -1.44 % | $ 47.3 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 100.0 | 0.2 % | $ 6.75 B | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 68.8 | -0.6 % | $ 3.67 B | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 675.22 | 0.9 % | $ 19.5 B | USA |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 667.03 | -0.07 % | $ 34.4 B | Schweiz |
 |
ENDRA Life Sciences
NDRA
|
3.66 M | $ 4.86 | 1.25 % | $ 3.82 M | USA |
 |
Neogen Corporation
NEOG
|
2.51 B | $ 12.31 | 0.98 % | $ 2.68 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 22.33 | 1.82 % | $ 500 M | USA |
 |
Natera
NTRA
|
30.5 B | $ 403.93 | 0.27 % | $ 55.2 B | USA |
 |
OPKO Health
OPK
|
1.04 B | $ 1.66 | 1.53 % | $ 1.25 B | USA |
 |
Precipio
PRPO
|
38.4 M | $ 19.23 | -3.9 % | $ 30.9 M | USA |
 |
RadNet
RDNT
|
5.62 B | $ 70.49 | 0.21 % | $ 5.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
10.1 B | $ 184.42 | -0.46 % | $ 14.5 B |  Irlanda |
 |
Senseonics Holdings
SENS
|
351 M | $ 7.6 | 1.2 % | $ 317 M | USA |